|
Age-at-analysis, years
|
47 (11, 24–64)
|
35 (9, 22–57)b
|
52 (4, 45–60)
|
52 (5, 42–62)
|
|
% Female
|
60%
|
40%
|
42%
|
38%
|
|
% Mild or moderate ID
|
0%
|
83%
|
79%
|
67%
|
|
CAMCOG scorea
|
NA
|
80/107 (11, 55–96, n = 31)
|
70/107 (13.8, 41–92, n = 11)c
|
59/107 (13.9, 39–87, n = 10)c
|
|
mCRT score (immediate)a
|
NA
|
35/36 (1.5, 30–36, n = 30)
|
20/36 (11.2, 0–36, n = 12)c
|
15/36 (7.9, 0–32, n = 11)c
|
|
mCRT score (delayed)a
|
NA
|
12/12 (0.9, 8–12, n = 31)
|
6/12 (3.8, 0–12, n = 13)c
|
4/12 (3.3, 0–12, n = 11)c
|
|
CSF Aβ42:40 ratio
|
0.11 (0.01, 0.08–0.12)
|
0.09 (0.02, 0.04–0.12)b
|
0.05 (0.01, 0.03–0.08)b
|
0.05 (0.01, 0.04–0.08)b
|
|
CSF p-tau pg/ml
|
36 (8, 22–54)
|
35 (24, 10–122)
|
145 (86, 22–304)b
|
158 (82, 31–323)b
|
|
CSF t-tau pg/ml
|
243 (57, 167–366)
|
295 (166, 86–671)
|
936 (658, 118–2565) b
|
959 (500, 212–1988) b
|
|
CSF NFL pg/ml
|
NA
|
355 (234, 65–1036)
|
1071 (767, 313–3123)
|
1387 (832, 627–3957)
|
